VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Gentium S.p.A. (NASDAQ:GENT) (the Company) today announced the publication of an independent study showing that Defibrotide may prevent hepatic veno-occlusive disease (VOD) associated with infantile osteopetrosis. The article, entitled, “Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with Defibrotide,” was published in the September 2006 issue of Bone Marrow Transplantation. The study was led by S. Corbacioglu, Department of Pediatrics, University of Ulm, Ulm, Germany.
